AbbVie Treats First Patient With Investigational ABBV-383 In Phase 3 CERVINO Study For Relapsed/Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
AbbVie has initiated the treatment of the first patient with its investigational drug ABBV-383 in the Phase 3 CERVINO study for relapsed/refractory multiple myeloma. The study will compare the efficacy, safety, and tolerability of ABBV-383 monotherapy against standard available therapies in patients who have undergone at least two prior treatments.
June 05, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has started treating the first patient in its Phase 3 CERVINO study for the investigational drug ABBV-383, aimed at relapsed/refractory multiple myeloma. This could potentially lead to a new treatment option if successful.
The initiation of a Phase 3 trial for ABBV-383 indicates significant progress in AbbVie's drug development pipeline. Positive outcomes from this trial could lead to a new treatment option for multiple myeloma, potentially boosting AbbVie's market position and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100